RAPP · NASDAQ · Biotechnology

Rapport Therapeutics (RAPP)

Develops RAP-targeted neuromedicines, with RAP-219 advancing across seizure and bipolar mania programs.

$34.50
vs last close−6.98 (−16.82%)